­

Doporučené postupy psychiatrické péče
Psychiatrické společnosti ČLS JEP

Stáhnout kapitolu v PDF

Autoři: Tomáš Kašpárek, Libor Ustohal

Garanti: Tomáš Kašpárek, Libor Ustohal

Oponent: Pavel Mohr

 

Léčba akutní fáze schizofrenie

Vysvětlivky:
ovál - nadpis 
kosočtverec - výběr z více variant
přerušovaná čára - diagram pokračuje na další straně 

 

Závěrečný komentář

Léčba akutní exacerbace schizofrenie často vyžuduje intenzivní farmakoterapii, která je klíčovým prvkem této fáze léčby. Vedle toho je však zásadní již od začátku nemoci zahájit psychosociální rehabilitaci, práci na náhledu nemoci a adherenci; práce s rodinami pacientů v tomto smyslu má velký význam pro dlouhodobý průběh nemoci. Současně jsou vhodné aktivizační přístupy formou různých metod ergoterapie, nácvik sociálních dovedností i specifické psychoterapeutické přístupy zaměřené na zvládání příznaků. Akutní léčba má být plánována s ohledem na specifika jednotlivých pacientů, jak z pohledu individuální účinnosti, citlivosti vůči nežádoucím účinkům a korobidity, tak z pohledu potřeb následné léčby v konkrétním prostředí pacienta, jeho funkční kapacity a sociálního zázemí. Přestože je většinou nutná hospitalizace pacienta, je potřeba pracovat na zachování schopnosti samostatného života v komunitě a pokud je možné, využívat alternativy akutní hospitalizace (krizová lůžka, denní stacionáře, asertivní komunitní týmy), či hospitalizace v rámci akutních lůžek všeobecných nemocnic.

Reference

Alameda L, Golay P, Baumann P, Morandi S, Ferrari C, Conus P, Bonsack C. Assertive outreach for "difficult to engage" patients: A useful tool for a subgroup of patients in specialized early psychosis intervention programs. Psychiatry Res. 2016 May 30;239:212-9.

Ali A, Carre A, Orri M, Urbach M, Barry C, Hassler C, Falissard B, Berthoz S, Nordon C. The real-life effectiveness of psychosocial therapies on social autonomy in schizophreniapatients: Results from a nationwide cohort study in France. Psychiatry Res. 2017 Jan;247:97-104.

Andrade C, Kisely S, Monteiro I, Rao S. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res. 2015 Jan;60:14-21.

Barber S, Olotu U, Corsi M, Cipriani A. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2017 Mar;3:CD006324.

Bauml J, Pitschel-Walz G, Volz A, Lüscher S, Rentrop M, Kissling W, Jahn T. Psychoeducation Improves Compliance and Outcome in Schizophrenia Without an Increase of Adverse Side Effects: A 7-Year Follow-up of the Munich PIP-Study. Schizophr Bull. 2016 Jul;42 Suppl 1:S62-70.

Citrome L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother. 2012 Aug;13(11):1545-73.

Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003 Jun;60(6):553-64.

Dieterich M, Irving CB, Bergman H, Khokhar MA, Park B, Marshall M. Intensive case management for severe mental illness. Cochrane Database Syst Rev. 2017 Jan 6;1:CD007906.

Dold M, Fugger G, Aigner M, Lanzenberger R, Kasper S. Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Res. 2015 Aug;166(1-3):187-93.

Dold M, Li C, Gillies D, Leucht S. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol. 2013 Sep;23(9):1023-33.

Dundar Y, Greenhalgh J, Richardson M, Dwan K. Pharmacological treatment of acute aitation associated with psychotic and bipolar disorder: a systematic review and meta-analysis. Hum Psychopharmacol. 2016 Jul;31(4):268-85.

Galling B, Roldan A, Hagi K, Rietschel L, Walyzada F, Zheng F, Zheng W, Cao XL, Xiang YT, Zink M, Kane JM, Nielsen J, Lechut S, Correll CU. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017 Feb;16(1):77-89.

Gibson RC, Walcott G. Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006570.

Gillies D., Sampson S., Beck A, Rathbone J. Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD003079.

Honer WG, Jones AA, Thornton AE, Barr AM, Procyshyn RM, Vila-Rodriguez F. Response trajectories to clozapine in a secondary analysis of pivotal trials support using treatment response to subtype schizophrenia. Can J Psychiatry. 2015 Mar; 60(3 Suppl 2):S19-25.

Chen AT, Chibnall JT, Nasrallah HA. A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: possible stage-specific effects. Ann Clin Psychiatry. 2015 Nov;27(4):289-96.

Kishi T, Iwata N. Efficacy and tolerability of histamine-2 receptor antagonist adjunction of antipsychotic treatment in schizophrenia: a meta-analysis of randomized placebo-controlled trials. Pharmacopsychiatry.2015 Jan;48(1):30-6.

Kishi T, Matsuda Y, Iwata N. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Psychopharmacology (Berl).2017 Jul;234(14):2113-2125.

Kishi T, Meltzer HY, Iwata N. Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis. Int J Neuropsychopharmacol. 2013 Jul;16(6):1259-66.

Kishi T, Mukai T, Matsuda Y, Moriwaki M, Iwata N. Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials. J Psychiatry Res. 2013 Nov;47(11):1557-63.

Lally J, Tully J, Robertson D, Stubbs B, Gaughran F, MacCabe JH. Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2016 Mar;171(1-3):215-24.

Lecomte T, Corbière M, Simard S, Leclerc C. Merging evidence-based psychosocial interventions in schizophrenia. Behav Sci (Basel). 2014 Nov 6;4(4):437-47.

Lefaucheur JP, André-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 2014;125(11):2150-2206.

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 Sep;382(9896):951-62.

Luecht S, Helfer B, Dold M, Kissling W, McGrath J. Carbamazepine for schizophrenia. Cochrane Database Syst Rev. 2014 May;2(5):CD001258.

Leucht S, Helfer B, Dold M, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database Syst Rev. 2015 0ct;28(10):CD003834.

Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bacher S, Cipriani A, Geddes JR, Salanti G, Davis JM. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regresssion of efficacy predictors. Am J Psychiatry. 2017 May. doi 10.1176/appi.ajp.2017.16121358. Epub ahead of print.

Luchini F, Medda P, Mariani MG, Mauri M, Toni C, Perugi G. Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response. World J Psychiatry. 2015 Jun 22;5(2):182-92.

McFarlane WR. Family Interventions for Schizophrenia and the Psychoses: A Review. Fam Process. 2016 Sep;55(3):460-82.

Morin L, Franck N. Rehabilitation Interventions to Promote Recovery from Schizophrenia: A Systematic Review. Front Psychiatry. 2017 Jun 12;8:100.

Nielsen RE, Levander S, Kjaersdam Telléus G, Jensen SO, Ostergaard Christensen T, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia - a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 2015 Mar;131(3):185-96.

Okuyama Y, Oya K, Matsunaga S, Kishi T, Iwata N. Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2016 Dec;12:3221-3236.

Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE, Hu Y, Maayan N, Adams CE. Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev. 2017 Jun 28;6:CD009005.

Ostinelli EG, Brooke-Powney MJ, Li X, Adams CE. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev. 2017 Jul 31;7:CD009377.

Revell ER, Neill JC, Harte M, Khan Z, Drake RJ. A systematic review and meta-analysis of cognitive remediation in early schizophrenia. Schizophr Res. 2015 Oct;168(1-2):213-22.

Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, Leucht S. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016 Mar;73(3):199-210.

Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, Möller HJ, Pelayo-Terán JM, Riedel M, Rujescu D, Schimmelmann BG, Serretti A, Correll CU, Leucht S. Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. Volume 172, Issue 7, July 01, 2015, pp. 617-629.

Sing J, Kour K, Jayaram MB. Acetylcholinestrase inhibitors for schizophrenia. Cochrane Database Syst Rev. 2012 Jan 18;1:CD007967.

Siskind D, McCarney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic reveiw and meta-analysis. Br J Psychiatry. 2016 Nov;209(5):385-392.

Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry. 2017 Jan; doi 10.1177/0706743717718167 Epub ahead of print.

Sommer IE, de Witte L, Begemann M, Kahn RS. Nonsteroidal anti-inflamatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012 Apr;73(4):414-9.

Souza JS, Kayo M, Tassell I, Martins CB, Elkis H. Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analysis. CNS Spectr. 2013 Apr; 18(2):82-9.

Taylor DM, Smith L, Gee SH, Nielsen J. Augmentation of clozapine with a second antipsychoti - a meta-analysis. Acta Psychiatr Scand. 2012 Jan;125(1):15-24.

Vidal C, Reese C, Fischer BA, Chiapelli J, Himelhoch S. Meta-analysis of efficacy of mirtazapine as an adjunctive treatment of negative symptoms of schizophrenia. Clin Schizophr Relat Psychoses. 2015 Summer;9(2):88-95.

Wang Y, Xia J, Helfer B, Li C, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev. 2016 Nov;11:CD004028.

Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011 May;168(5):472-85.

Xiang YQ, Zheng W, Wang SB, Yang XH, Cai DB, Ng CH, Ungvari GS, Kelly DL, Xu WY, Xieng YT. Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol. 2017 Jan;27(1):8-18.

Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013 Jul;16(6):1205-18.

Zheng W, Cao XL, Ungvari GS, Xiang YQ, Guo T, Liu ZR, Wang YY, Forester BP, Seiner SJ, Xiang YT. Electroconvulsive therapy added to non-clozapine antipsychotic medication for treatment resistant schizophrenia: meta-analysis of randomized controlled trials. PLoS One. 2016 Jun;11(6):e0156510.

Zheng W, Xiang YT, Yang XH, Xiang YQ, de Leon J. Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Clin Psychiatry. 2017 May;78(5):e498-e505.

Zheng W, Zheng YJ, Li XB, Tang YL, Wang CY, Xiang YQ, de Leon J. Efficacy and safety of adjunctive aripiprazole in schizophrenia: meta-analysis of randomized controlled trials. J Clin Psychopharmacol. 2016 Dec;36(6):628-636.

Zhu Y, Li C, Huhn M, Rothe P, Kraus M, Bighelli I, Schneider-Thoma J, Leucht S. How well do patients with a first episode schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017 Sep;27(9):835-844.

Datum zveřejnění: 20.9.2018

­